U.S. Markets closed
  • S&P 500

    4,473.75
    -6.95 (-0.16%)
     
  • Dow 30

    34,751.32
    -63.07 (-0.18%)
     
  • Nasdaq

    15,181.92
    +20.42 (+0.13%)
     
  • Russell 2000

    2,235.28
    +0.83 (+0.04%)
     
  • Crude Oil

    72.61
    0.00 (0.00%)
     
  • Gold

    1,754.70
    -40.10 (-2.23%)
     
  • Silver

    22.61
    -1.15 (-4.84%)
     
  • EUR/USD

    1.1772
    -0.0054 (-0.4591%)
     
  • 10-Yr Bond

    1.3310
    +0.0270 (+2.07%)
     
  • Vix

    18.36
    +0.18 (+0.99%)
     
  • GBP/USD

    1.3794
    -0.0041 (-0.2980%)
     
  • USD/JPY

    109.7000
    +0.3400 (+0.3109%)
     
  • BTC-USD

    47,523.11
    -649.41 (-1.35%)
     
  • CMC Crypto 200

    1,221.40
    -11.89 (-0.96%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Nikkei 225

    30,323.34
    -188.36 (-0.62%)
     

Recap: Baxter International Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Baxter International (NYSE:BAX) moved higher by 0.3% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 1700.00% over the past year to $0.80, which beat the estimate of $0.76.

Revenue of $3,181,000,000 rose by 4.67% year over year, which beat the estimate of $3,040,000,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $3.35 and $3.43.

The upcoming fiscal year's revenue expected to be between $12,490,000,000 and $12,607,000,000.

Details Of The Call

Date: Feb 04, 2021

View more earnings on BAX

Time: 08:30 AM

ET Webcast URL: https://www.directeventreg.com/der/validateConferenceId.action

Recent Stock Performance

52-week high: $95.19

Company's 52-week low was at $69.10

Price action over last quarter: down 0.10%

Company Description

Baxter manufactures medical products across seven major reported business segments. The renal segment (32% of 2019 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while its acute therapies segment (5%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (25% of sales) sells IV pumps, administrative sets, and solutions while its nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segment (19% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (8% of sales) provides hemostastic products and biosurgical sealants. Contract manufacturing rounds out the remaining sales.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.